Merck Sharp and Dohme NZ - Latest News [Page 1]

NZ 2nd in the world to register KEYTRUDA - chemo combination

Monday, 17 July 2017, 12:49 pm | Merck Sharp and Dohme NZ

New Zealand second in the world to register KEYTRUDA® - chemo combination July 14 , 2017, New Zealand follows the United States Food and Drug Administration (FDA) in being the second country worldwide to register KEYTRUDA® (pembrolizumab) in combination ... More >>

New medicine to fight Hepatitis C now registered

Thursday, 15 December 2016, 12:43 pm | Merck Sharp and Dohme NZ

15 December 2016, Merck Sharp & Dohme (New Zealand) Ltd (MSD) today announced ZEPATIER® (elbasvir/grazoprevir) has been registered by Medsafe for the treatment of chronic Hepatitis C – genotype 1, 3* and 4 infection in adults. Hepatitis C ... More >>

KEYTRUDA now registered to treat lung cancer

Monday, 29 August 2016, 10:26 am | Merck Sharp and Dohme NZ

August 29th 2016, MSD today announced that its anti-PD1 immunotherapy KEYTRUDA®(pembrolizumab) has been registered by Medsafe for New Zealand patients who have previously been treated for advanced non-small cell lung cancer (NSCLC) and whose tumours express ... More >>

Kiwis get rare opportunity to help protect against shingles

Friday, 9 March 2012, 2:29 pm | Merck Sharp and Dohme NZ

New Zealanders will soon have access to a limited supply of a vaccine to help protect against shingles, despite a global shortage of the vaccine. More >>

ISENTRESS Now Funded for NZ HIV Patients

Thursday, 1 October 2009, 4:57 pm | Merck Sharp and Dohme NZ

New Zealand HIV patients will now have another fully funded treatment option thanks to PHARMAC reimbursing ISENTRESSTM (raltegravir) from 1 October 2009. More >>

ISENTRESS Awarded Prix Galien USA Top Honor

Friday, 24 October 2008, 12:40 pm | Merck Sharp and Dohme NZ

Merck Sharp & Dohme's medicine for HIV/AIDS, recently received the Prix Galien USA 2008 Award for Best Pharmaceutical Agent. More >>

Many HIV-Positive Patients Still Fear Stigma

Thursday, 25 September 2008, 11:37 am | Merck Sharp and Dohme NZ

Results from the AIDS Treatment for Life International Survey (ATLIS), which polled nearly 3,000 HIV-positive patients from New Zealand and 17 other countries, show many people living with HIV and AIDS still live in fear of the societal stigma that ... More >>

Osteoporosis Medication Now Registered

Wednesday, 9 July 2008, 12:15 am | Merck Sharp and Dohme NZ

Merck Sharp & Dohme New Zealand (MSDNZ) has gained registration for its osteoporosis medication FOSAMAX PLUS™ 5600 IU. More >>

Maxalt MLT Now Fully Funded For Migraine Sufferers

Friday, 30 May 2008, 10:36 am | Merck Sharp and Dohme NZ

The estimated 400,000[ ] New Zealanders who suffer from migraine now have another choice of fully funded medication to battle this debilitating disorder. More >>

First DPP-4 Inhibitor for Type 2 Diabetes in NZ

Thursday, 28 February 2008, 3:26 pm | Merck Sharp and Dohme NZ

New Zealanders with Type 2 diabetes now have access to a new medicine which is significantly less likely to cause weight gain or dangerously low blood sugar; thanks to Merck Sharp & Dohme New Zealand's (MSDNZ) once-daily tablet, JANUVIA® (sitagliptin, MSD), ... More >>

Merck to Donate Three Million Doses of Gardasil

Wednesday, 17 October 2007, 10:43 am | Merck Sharp and Dohme NZ

Merck to Donate Three Million Doses of Gardasil®, its Cervical Cancer Vaccine, to Support Vaccination Programmes in Lowest Income Nations More >>

Final MEDAL Programme Results

Tuesday, 14 November 2006, 12:23 am | Merck Sharp and Dohme NZ

Large Outcomes Study Showed Merck & Co., Inc.'s ARCOXIA® (etoricoxib) Had Similar Rates of Cardiovascular Thrombotic Events Compared to Diclofenac, the Most Prescribed Traditional NSAID Worldwide In the Study, ARCOXIA Was Shown to Have Significantly ... More >>

Osteoporosis Medicine Decision Welcomed

Tuesday, 27 September 2005, 12:19 am | Merck Sharp and Dohme NZ

The decision to widen taxpayer-funded access to the osteoporosis medication Fosamax® will result in significant quality of life improvements for the estimated 30% of New Zealand women over the age of 50 who have osteoporosis. More >>

Shelford Committed To Influenza Vaccination

Monday, 9 May 2005, 11:28 am | Merck Sharp and Dohme NZ

Former All-Black captain, Buck Shelford says he’s committed to the “You’re never too fit to get hit” influenza vaccination campaign which starts tonight because of his personal experience with the potentially-deadly virus. More >>

Merck Statement on COX-2 Inhibitors

Friday, 29 April 2005, 2:45 pm | Merck Sharp and Dohme NZ

Alister Brown, managing director of Merck Sharp & Dohme New Zealand (MSD NZ), made the following comments in response to today’s announcement by the Ministry of Health that COX-2 inhibitors will remain available in New Zealand: More >>

Influenza Vaccine Deliveries On Track

Wednesday, 20 April 2005, 1:06 pm | Merck Sharp and Dohme NZ

Merck Sharp & Dohme NZ said that it expected to clear the backlog of reconfirmed VAXIGRIP® influenza vaccine orders from its distribution centre by late afternoon today. More >>

Medsafe Coxib Review

Tuesday, 22 February 2005, 10:45 pm | Merck Sharp and Dohme NZ

“We recognize that the cardiovascular safety of the coxib and NSAID classes is an important public health issue. The data suggest an increased cardiovascular risk vs. placebo is a class effect. At the present time it is unclear if the class of ... More >>

Merck Realigns Distribution In New Zealand

Friday, 17 September 2004, 5:02 pm | Merck Sharp and Dohme NZ

Merck Limited, the New Zealand operation of Merck KGaA, one of the world’s largest pharmaceutical, laboratory consumables and specialized chemical multinational manufacturers and suppliers, has terminated its agency agreement with Biolab Limited in New Zealand, ... More >>

New Cholesterol-Lowering Drugs Available

Tuesday, 8 June 2004, 4:09 pm | Merck Sharp and Dohme NZ

New Zealanders with high cholesterol will benefit from a new agreement signed between the Pharmaceutical Management Agency (PHARMAC) and pharmaceutical company Merck Sharp & Dohme New Zealand (MSD NZ). More >>

 

InfoPages Links

 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL